The hyperscalers are just beginning to figure out the consequences of the AI arms race, and now everyone seems to be against them.
Stocktwits on MSN
Zymeworks to buy Theravance Biopharma in $929M deal – a look at what this deal means for TBPH shareholders
The firm added that the price per share represents a 22% premium over the stock’s closing price on March 3, 2026. ・The transaction is expected to close in the second half of 2026. ・On March 3, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results